Insider · CIK 0001914503
Eric Easom
ceoofficerdirector
Files at ANTX (AN2 Therapeutics, Inc.). First filing Nov 18, 2024, latest Jun 3, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 1
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
2 / 0
$61k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANTX: AN2 Therapeutics, Inc.
ANTXOct 9, 2026 · close 4.40
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | AN2 Therapeutics, Inc. | $11k 10,000 shares | +4% | +6% from low-37% from high | |
| 47Moderate | AN2 Therapeutics, Inc. | $50k 50,000 shares | +5% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +249,999 | - | - | 249,999 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -249,999 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +225,000 | - | - | 225,000 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -225,000 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +267,650 | - | - | 267,650 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -267,650 | - | - | 0 | Mar 23, 2026 |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +112,250 | $0.00 | $0 | 368,630 | Feb 23, 2026 |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +224,500 | $0.00 | $0 | 224,500 | Feb 23, 2026 |
| Jun 2, 2025 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stock | +10,000 | $1.07 | $11k | 256,380 | Jun 3, 2025 |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +145,250 | $0.00 | $0 | 246,380 | Feb 28, 2025 |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +290,500 | $0.00 | $0 | 290,500 | Feb 28, 2025 |
| Nov 18, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +50,000 | $1.00 | $50k | 1,065,766 | Nov 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.